IMUGENE LIMITED — Capital/Financing Update 2012

Jul 30, 2012

==> picture [207 x 80] intentionally omitted <==

Imugene announces completion of acquisition of Linguet, finalises share placement & Board a ointment pp

Highlights:

• ACQUISITION OF LINGUAL CONSEGNA

• FINALISATION OF SHARE PLACEMENT

• APPOINTMENT AND RESIGNATION OF DIRECTOR

• CHANGE OF COMPANY SECRETARY

Perth, 31 July 2012 : Imugene Limited (ASX:IMU) is pleased to announce the completion of the acquisition of 100% of the issued share capital of the drug delivery technology company Lingual Consegna Pty Limited from the Consegna Group Limited (“Consegna”). The consideration for the acquisition was 100,000,000 fully paid ordinary shares in the Company to Consegna.

Lingual Consegna owns the rights to a family of patents and patent applications that protect the core drug delivery platform technology Linguet that has application in the human and animal pharmaceutical and nutraceutical industries.

The Company has also finalised the share placement and will proceed to allot and issue 100,000,000 shares to sophisticated investors at an issue price of $0.01 per share to raise $1,000,000. These funds will be used towards funding of the expanded Imugene drug delivery technologies and general working capital. In addition, 50,000,000 options exercisable at $0.02 on or before 31 December 2015 will be granted at a price of 0.01 cent each. The share placement was arranged by CPS Securities and Forrest Capital.

Mr Fabio Pannuti has been appointed as Executive Chairman of Imugene Limited and Mr Graham Dowland is stepping down from the Board and as Chairman.

Warwick Lamb, Managing Director commented, “ I would like to take this opportunity on behalf of the Board and shareholders to thank Graham Dowland for his commitment and stewardship of Imugene over the years and at the same time welcome Fabio Pannuti to the Board, he will be invaluable for the new direction of Imugene Limited ”.

Mr Pannuti is Managing Director of Consegna Group Limited. He has an extensive experience building companies across a number of industries including the biomedical and drug delivery markets, HR and labour hire, telephony, property development, mineral resources, agriculture and construction. He has had direct experience in many mergers and outdoor media agency in Eastern Europe. Many of the assets have been listed on public markets on North American, European and Australian Exchanges.

ABN 99 009 179 551

Registered Office Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000 Tel +61 8 9440 2660 Fax +61 8 9440 2699

www.imugene.com

Mr Justyn Stedwell has been appointed as Company Secretary of Imugene Limited, whilst Ms Julie Foster has stepped down from the position.

Mr Stedwell is a professional Company Secretary with over six years’ experience as a Company Secretary in ASX listed companies within various industries including IT & Telecommunications, Biotechnology, and Mining. He is currently also the Company Secretary of ASX listed companies Consegna, Group Limited, Anittel Group Limited, Fortis Mining Limited, Motopia Limited and Solagran Limited.

He has completed a Bachelor of Business & Commerce (Management & Economics) at Monash University, a Graduate Diploma of Accounting and Deakin University, a Graduate Diploma in Applied Corporate Governance with Chartered Secretaries Australia and Graduate Certificate of Applied Finance with Kaplan Professional.

Notice under section 708A(5)(e) of the Corporations Act 2001

This notice is given by Imugene Limited (ACN 009 179 551) (Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

• (a) it today issued 100,000,000 fully paid ordinary shares (Shares) to Consegna Group Limited (ACN 107 903 159) (Consega) pursuant to a share sale agreement with Consegna for the acquisition of 100% of the issued share capital of Lingual Consegna Pty Ltd (ACN 152 438 554), as previously announced on 1 May 2012;

• (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

• (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;

• (d) as at the date of this notice the Company has complied with:

  • (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and section 674 of the Corporations Act as it applies to the Company; and

  • (ii) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Page 2 of 3

ENDS

For more information please visit the Imugene Website www.imugene.com or contact:

Dr Warwick Lamb Managing Director +61 8 9440 2660

About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) LinguetTM technology. LinguetTM is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products. Imugene also currently specialises in the development and commercialisation of novel animal health products for pigs and poultry. The range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock.

Page 3 of 3